8-K: Sagimet Advances MASH, Acne & Cancer Programs

Sagimet Biosciences Inc. updated its investor presentation, highlighting progress in its MASH, acne, and oncology programs, including positive Phase 2b denifanstat data and new combination trials.

Summary

• Sagimet Biosciences Inc. updated its investor presentation on October 23, 2025, detailing progress across its therapeutic pipeline.
• Denifanstat, a novel fatty acid synthase (FASN) inhibitor, is the lead molecule targeting metabolic dysfunction-associated steatohepatitis (MASH), acne, and cancer.
• Denifanstat successfully met both primary endpoints in its Phase 2b FASCINATE-2 trial for MASH, demonstrating significant reduction in fibrosis.
• A Phase 1 clinical trial evaluating the pharmacokinetics (PK) and tolerability of a combination of denifanstat and resmetirom for MASH was initiated in September 2025, with data expected in 1H 2026.
• TVB-3567, a follow-on FASN inhibitor for acne, received Investigational New Drug (IND) clearance in March 2025, and a first-in-human Phase 1 clinical trial began in June 2025.
• Ascletis, Sagimet's license partner for China, completed a Phase 3 trial for denifanstat in moderate to severe acne vulgaris, meeting all primary and secondary endpoints, and plans to submit a New Drug Application (NDA) soon.
• The company reported $135.5 million in cash on hand as of June 30, 2025, which is expected to fund current operations through 2027.
• Intellectual property for denifanstat, TVB-3567, and the denifanstat/resmetirom combination extends to various dates, with some potential Patent Term Extensions (PTEs) to 2048.
• The oncology program focuses on FASN-dependent tumor types, including GBM, Prostate, HCC, and KRASM NSCLC, with ongoing Phase 1 trials and preclinical work.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for denifanstat in MASH, including meeting primary and multiple secondary endpoints in a Phase 2b trial, and for denifanstat in acne from a partner's Phase 3 trial. The initiation of combination trials and new drug development (TVB-3567) indicates active pipeline progression. A solid cash position provides a good runway through 2027. While there are minor adverse events and a program cessation in oncology, the overall clinical progress and strategic pipeline development are very compelling.

Positives

• Denifanstat met both primary endpoints in the Phase 2b FASCINATE-2 trial for MASH, demonstrating significant reduction in fibrosis.
• Denifanstat achieved statistical significance at Week 52 for NAS ≥ 2 points improvement without worsening of fibrosis (mITT: 52% vs 20% placebo, p=0.0003) and MASH resolution + NAS ≥ 2 improvement without worsening of fibrosis (mITT: 36% vs 13% placebo, p=0.0035).
• Statistically significant improvement in liver fibrosis by ≥ 1 stage without worsening of MASH (mITT: 41% vs 18% placebo, p=0.0102).
• Statistically significant resolution of MASH without worsening of fibrosis (mITT: 38% vs 16% placebo, p=0.0043).
• Denifanstat showed statistically significant improvement in fibrosis for F3 patients (49% vs 13% placebo, p=0.0032) and >2 stage improvement (mITT: 20% vs 2% placebo, p=0.0065).
• Progression to cirrhosis (F4) was significantly lower in the denifanstat group (5% vs 11% placebo, p=0.0386).
• Denifanstat achieved statistically significant VCTE improvement at Weeks 26 and 52.
• AI-based digital pathology showed denifanstat significantly reduced fibrosis in advanced patients, with 85% of qF4 patients showing 1 to 2-stage reductions.
• Denifanstat was generally well-tolerated in FASCINATE-2, with no drug-induced liver injury (DILI) signal or muscle wasting detected, and gastrointestinal (GI) effects comparable to placebo.
• Denifanstat significantly decreased liver fat by MRI-PDFF (65% vs 21% placebo, p<0.0001) and reduced FAST score.
• Denifanstat decreased ALT and AST liver enzyme levels.
• Denifanstat decreased LDL-c levels and increased polyunsaturated triglycerides.
• Denifanstat reduced de novo lipogenesis (tripalmitin biomarker) as early as week 4 of treatment.
• Pre-clinical data demonstrated a synergistic effect of the combination of a FASN inhibitor and resmetirom in MASH mouse models.
• Denifanstat improved MASH resolution and fibrosis in patients on stable GLP1-RA at baseline.
• A Phase 1 clinical trial for the denifanstat/resmetirom combination was initiated in September 2025.
• TVB-3567 received IND clearance in March 2025 and initiated its first-in-human Phase 1 trial in June 2025 for acne.
• Ascletis's Phase 3 trial for denifanstat in acne met all primary and secondary endpoints, with comparable treatment-emergent adverse events (TEAEs) to placebo.
• A strong intellectual property portfolio is in place, with patents extending to 2048 for combination therapy.
• A cash position of $135.5 million as of June 30, 2025, is expected to fund operations through 2027.
• Denifanstat received FDA Breakthrough Therapy designation for MASH.

Negatives

• Hair thinning was an adverse event for denifanstat in the FASCINATE-2 trial (18.8% in denifanstat group vs 3.6% placebo), leading to discontinuation in 7% of patients.
• Dry eye (10.9% vs 8.0% placebo) and dry skin (6.3% vs 2.9% placebo) were noted in Ascletis's acne trial.
• Ascletis announced the cessation of its China GBM (glioblastoma) program in August 2025.
• Cross-trial comparisons for combination therapy benefits are not possible due to differences in trial design and patient populations.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from projections.
• The clinical development and therapeutic potential of drug candidates (denifanstat, TVB-3567, or any other) may not be fully realized.
• Topline clinical trial data may not be predictive of, and may differ from, final clinical data and later-stage clinical trials.
• The ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines is uncertain.
• Unfavorable new clinical trial data may emerge in other clinical trials of product candidates.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The relationship with Ascletis and the success of its development efforts for denifanstat are subject to risks.
• The accuracy of estimates regarding capital requirements is a risk.
• The ability to maintain and successfully enforce adequate intellectual property protection is crucial.
• Adverse events such as hair thinning, dry eye, and dry skin were observed in trials and could impact patient adherence or regulatory approval.

Future Outlook

Expect data readout for the Phase 1 denifanstat/resmetirom combination trial in 1H 2026. The goal is to initiate a TVB-3567 Phase 2 trial in acne in 2026, subject to regulatory consultation and Phase 1 outcome. Plans are in place to consult with the US FDA by early 2026 on using Ascletis's Phase 3 data for denifanstat in acne. Ascletis plans to submit an NDA for denifanstat in acne soon in China. The company will continue developing tripalmitin and additional markers as potential biomarkers for denifanstat treatment response and is identifying FASN-dependent tumor types for potential FASN inhibitor development in oncology. There is also potential for a Phase 2 proof of concept in F4 MASH patients for denifanstat.

Management Comments

• We do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as required by applicable law.
• If the outcome of this Phase 1 trial [denifanstat/resmetirom] is positive, we will explore moving into the development of a combination product for patients living with MASH.

Industry Context

MASH is a burgeoning epidemic with a complex, heterogeneous patient population, representing a significant opportunity for differentiated mechanisms of action. The global acne market is expected to reach $17 billion in the next decade, with dermatologists open to new therapies, especially for moderate to severe cases and chronic management. FASN inhibition is an attractive therapeutic target for acne due to its role in sebum production and inflammation. FASN also plays a key role in cancer, supporting tumor survival, proliferation, and establishing drug resistance, particularly in FASN-dependent tumor types. The development of combination therapies, especially with approved drugs like resmetirom (the first FDA-approved MASH drug) and GLP-1s, aligns with broader industry trends for addressing complex diseases like MASH.

Comparison to Industry Standards

• Denifanstat's safety profile regarding hair thinning (7% discontinuation rate) was compared to GLP-1s, which range from 7% to 10% for this adverse event.
• The combination of denifanstat and resmetirom is positioned as complementary, with resmetirom being the first FDA-approved drug for non-cirrhotic MASH, indicating a strategy to leverage an established market leader.
• The presentation highlights the potential synergies in the mechanisms of action between denifanstat (FASN inhibitor, reduces de novo lipogenesis and fibrogenesis) and resmetirom (THR-beta agonist, increases fatty acid oxidation and improves mitochondrial function).
• MASH treatment goals across fibrosis staging (F1-F4) are aligned with current medical guidelines from organizations such as Endocr Pract, Hepatology, and EASL.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, pipeline progression, and extended cash runway, potentially increasing company valuation and future revenue streams.
• Patients (MASH): Potential for new, effective treatment options, including a combination therapy, especially for advanced fibrosis stages.
• Patients (Acne): Potential for a novel oral treatment for moderate to severe acne.
• Employees: Continued employment and potential growth opportunities as the pipeline advances.
• Regulatory Authorities: Ongoing engagement for trial designs and NDA submissions.

Next Steps

• Data readout for Phase 1 denifanstat/resmetirom combination trial expected 1H 2026.
• Subject to regulatory consultation, a Phase 2 clinical combination study with denifanstat and resmetirom in F4 MASH patients is planned.
• Upon completion of TVB-3567 Phase 1, consult with regulatory authorities regarding Phase 2 trial design for acne, with the goal of initiating Phase 2 in 2026.
• Plan to consult with the US FDA by early 2026 on the potential use of Ascletis Phase 3 data for denifanstat in acne.
• Ascletis plans to submit an NDA for denifanstat in acne soon in China.
• Continue development of tripalmitin and additional markers as potential biomarkers of treatment response for denifanstat.
• Identifying FASN-dependent tumor types for potential FASN inhibitor development in oncology.
• Potential Phase 2 proof of concept in F4 MASH patients for denifanstat.

Key Dates

Recommendation

The filing details highly positive clinical trial results for denifanstat in MASH, meeting both primary and multiple secondary endpoints, including significant fibrosis reduction. The initiation of a combination trial with resmetirom, the first FDA-approved MASH drug, positions Sagimet strategically. Furthermore, the successful Phase 3 data for denifanstat in acne from its China partner, coupled with plans for US FDA consultation, opens another significant market. The company's strong cash position provides a runway through 2027, mitigating near-term financing concerns. While there are minor adverse events and a program cessation in oncology, the overall clinical progress and strategic pipeline development are very compelling, suggesting significant upside potential for investors.

Keywords

MASH, Denifanstat, FASN inhibitor, Acne, Oncology, Fibrosis, Metabolic dysfunction-associated steatohepatitis, TVB-3567, Resmetirom, Clinical trials, Biotechnology, Pharmaceuticals, Drug development, Liver disease, Dermatology, Cancer therapy, SGMT